5,6-dihydro-benzo[f]quinoline-10-carboxylic acid methyl ester | 1303516-54-2

• 分子结构分类: 有机化合物 - 苯类化合物
• 英文名称: 5,6-dihydro-benzo[f]quinoline-10-carboxylic acid methyl ester
• 英文别名: Methyl 5,6-dihydrobenzo[f]quinoline-10-carboxylate
• CAS: 1303516-54-2
• 化学式: C₁₅H₁₃NO₂
• 分子量: 239.274
• InChiKey: STFLVKVIOPWCES-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• ARYL-AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE
  申请人：Eckhardt Matthias

  公开号：US20110136800A1

  公开（公告）日：2011-06-09

  The present invention relates to compounds defined by formula I wherein the variables R 1 , R 2 , R 3 , R 4 , and m are defined as in claim 1 , possessing valuable pharmacological activity. Particularly, the compounds are inhibitors of 11β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity, and dyslipidemia.

  本发明涉及由以下公式I定义的化合物，其中变量R1、R2、R3、R4和m的定义如权利要求书中，具有有价值的药理活性。特别地，这些化合物是11β-羟基类固醇脱氢酶（HSD）1的抑制剂，因此适用于治疗和预防可以受到该酶抑制影响的疾病，如代谢性疾病，特别是2型糖尿病、肥胖症和血脂异常。
• [EN] ARYL- AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE<br/>[FR] DÉRIVÉS ARYLECARBONYLE ET HÉTÉROARYLCARBONYLE D'HEXAHYDROINDÉNOPYRIDINE ET D'OCTAHYDROBENZOQUINOLINE
  申请人：VITAE PHARMACEUTICALS INC

  公开号：WO2011057054A1

  公开（公告）日：2011-05-12

  The present invention relates to compounds defined by formula I, wherein the variables R1, R2, R3, R4, and m are defined as in claim 1, possessing valuable pharmacological activity. Particularly, the compounds are inhibitors of 11 β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity, and dyslipidemia.

  本发明涉及由公式I定义的化合物，其中变量R1、R2、R3、R4和m如权利要求1中定义的那样，具有有价值的药理活性。特别是，这些化合物是11β-羟基类固醇脱氢酶（HSD）1的抑制剂，因此适用于治疗和预防可以受到该酶抑制影响的疾病，例如代谢性疾病，特别是2型糖尿病、肥胖症和血脂异常。
• [EN] CRYSTALLINE FORMS OF HYDROCHLORIDE SALT OF (4A-R,9A-S) -1- (1H - BENZOIMIDAZOLE- 5 -CARBONYL) -2, 3, 4, 4A, 9, 9A - HEXAHYDRO -1H- INDENO [2, 1 -B] PYRIDINE- 6 -CARBONITRILE AND THEIR USE AS HSD 1 INHIBITORS<br/>[FR] FORMES CRISTALLINES DU SEL DE TYPE CHLORHYDRATE DU (4A-R,9A-S)-1-(1H-BENZIMIDAZOLE-5-CARBONYL)-2,3,4,4A,9,9A-HEXAHYDRO-1H-INDÉNO[2,1-B]PYRIDINE-6-CARBONITRILE ET LEUR UTILISATION COMME INHIBITEURS D'HSD1
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012061708A1

  公开（公告）日：2012-05-10

  The present invention relates to crystalline compounds of the following structural formula (II) possessing valuable pharmacological activity. Particularly, the compounds are inhibitors of 11 β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity, and dyslipidemia.

  本发明涉及具有以下结构式（II）的晶体化合物，具有有价值的药理活性。特别地，这些化合物是11β-羟基类固醇脱氢酶（HSD）1的抑制剂，因此适用于治疗和预防可以受到该酶抑制影响的疾病，如代谢性疾病，特别是2型糖尿病、肥胖症和血脂异常。
• ARYL- AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE
  申请人：Vitae Pharmaceuticals, Inc./Boehringer-Ingelheim

  公开号：US20160272590A1

  公开（公告）日：2016-09-22

  The present invention relates to compounds defined by formula I wherein the variables R 1 , R 2 , R 3 , R 4 , and m are defined as in claim 1 , possessing valuable pharmacological activity. Particularly, the compounds are inhibitors of 11β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity, and dyslipidemia.

  本发明涉及由公式I定义的化合物，其中变量R1、R2、R3、R4和m的定义如权利要求书中所述，具有有价值的药理活性。特别地，这些化合物是11β-羟基类固醇脱氢酶（HSD）1的抑制剂，因此适用于治疗和预防可以受到该酶抑制影响的疾病，例如代谢性疾病，特别是2型糖尿病、肥胖症和血脂异常。
• ARYL- AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE AND THEIR USE AS HSD 1 INHIBITORS
  申请人：Vitae Pharmaceuticals, Inc.

  公开号：EP2496559B1

  公开（公告）日：2018-01-10